Securities code: 300358 securities abbreviation: Truking Technology Limited(300358) Announcement No.: 2022-015 Truking Technology Limited(300358)
Announcement on the establishment of chutiansiweikang gene technology (Changsha) Co., Ltd. the company and all members of the board of directors guarantee that the content of information disclosure is true, accurate and complete without false records, misleading statements or major omissions.
1、 Overview of the transaction
1. Overview of this investment
In order to further enhance the competitiveness of Truking Technology Limited(300358) (hereinafter referred to as "the company" or " Truking Technology Limited(300358) ") in the field of biopharmaceutical equipment, improve the company's development strategy of "one vertical, one horizontal and one platform", complete the company's biopharmaceutical equipment sector and product chain, and provide independent and controllable instruments, equipment, consumables and other products and services for Chinese gene therapy related pharmaceutical enterprises, The company plans to jointly invest with relevant parties to establish a company in Ningxiang City, Changsha, Hunan Province, with the main business of providing equipment, consumables and accessories related to cell processing system. The name of the joint venture is chutiansiweikang gene technology (Changsha) Co., Ltd. (hereinafter referred to as "chutiansiweikang"), with a registered capital of 50 million yuan. After the establishment of the company, Truking Technology Limited(300358) subscribed 25.5 million yuan, accounting for 51% of its equity. It is a holding subsidiary of Truking Technology Limited(300358) .
2. Approval procedures for this investment
According to the Shenzhen Stock Exchange GEM Listing Rules and the articles of association and other relevant provisions, this foreign investment is within the approval authority of the chairman of the company and does not need to be submitted to the board of directors or the general meeting of shareholders of the listed company for deliberation.
This foreign investment does not constitute a related party transaction or a major asset reorganization stipulated in the administrative measures for major asset reorganization of listed companies.
2、 Basic information of the proposed joint venture
1. Company name: truking siweikang gene technology (Changsha) Co., Ltd
2. Legal representative: Tan Liang
3. Registered capital: 50 million yuan only
4. Business scope: Biotechnology R & D, biotechnology services, technology transfer and technology consulting; R & D, production and sales of laboratory instruments and equipment and laboratory consumables; Development and technical services of computer software, information system software and database; Operate import and export business (excluding import distribution, state monopoly and specially controlled commodities). 5. Ownership structure
Name of shareholders proportion of subscribed capital contribution (10000 yuan)
Truking Technology Limited(300358) 2550 51%
Hu Biliang 1950 39%
Changsha Chutian Tongkang management partnership (limited partnership) 500 10%
Total 5000 100%
The above matters shall be subject to industrial and commercial registration.
3、 Overview of counterparties
1. Changsha truking Tongkang management partnership (limited partnership) is the shareholding platform of truking Sikang for talent introduction in the future.
2. Hu Biliang graduated from the University of science and technology of China in 2007 with a bachelor's degree in life sciences. In 2013, he received a doctorate from the University of Southern California. In 2014, he carried out postdoctoral research at the University of Pennsylvania and studied under Professor Carl June, the father of clinical cart. In 2018, he returned to China and founded Hunan siweikang Pharmaceutical Co., Ltd., which is one of the experts engaged in cart new drug research in the industry. It has no relationship with Truking Technology Limited(300358) directors, supervisors and senior managers.
4、 Impact and risk of this investment
1. The establishment of truking siweikang to enter the field of gene and precision treatment equipment, instruments and consumables is an inevitable measure of Truking Technology Limited(300358) "one vertical, one horizontal and one platform" and "2030" strategy. We will gradually develop T cell purification and treatment equipment, automatic immune cell culture equipment, immune cell preparation equipment, etc. at the same time, we will develop and supplement relevant products according to the needs of the company and customers. It will improve the overall solution capability of Truking Technology Limited(300358) and gradually develop from an equipment company to a high-tech technology platform company.
2. Before this cooperation, Truking Technology Limited(300358) has the ability of semi-automatic cell processing related equipment, instruments, consumables and so on, but has not yet formed a full-automatic intelligent cell processing overall solution. In the future, the R & D and manufacturing capacity of Truking Technology Limited(300358) and the pharmaceutical process experience of Hu Biliang and relevant personnel need to be combined to carry out the R & D of fully automatic cell processing equipment, instruments, consumables and overall solutions. In the future, it will face the challenge of new product development and the risk of product development failure may be encountered in the future.
3. After the product is launched, it still needs to be tested by customers and the market. In the short term, it is temporarily unable to bring income and profits and have a significant impact on the company's performance.
Please pay attention to the investment risk!
It is hereby announced.
Truking Technology Limited(300358) board of directors February 20, 2022
